Cargando…
Dissecting the biological heterogeneity of HER2-positive breast cancer
HER2-positive (HER2+) breast cancer (BC) is a heterogenous and multifaceted disease, with interesting therapeutic implications. First, all intrinsic molecular subtypes can be identified in HER2+ tumors, with the HER2-enriched being the most frequent. Such subtypes do not differ much from their count...
Autores principales: | Schettini, Francesco, Prat, Aleix |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374722/ https://www.ncbi.nlm.nih.gov/pubmed/34392185 http://dx.doi.org/10.1016/j.breast.2021.07.019 |
Ejemplares similares
-
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019) -
Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017) -
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022) -
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022) -
Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)